# Flare Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/flare-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.flaretx.com
- Total disclosed funding: $290M
- Latest round: Series C (Jul 6, 2026)
- Investors on record: 13

## About

Founded in 2021 and based in Massachusetts, US, Flare Therapeutics, Inc. is a biotechnology company that focuses on discovering medicines for cancer and other diseases. The firm was co-founded by Dr. Steven McKnight. In July 2026, Flare Therapeutics, Inc. raised USD 85 million in series C funding co-led by returning investors Third Rock Ventures, Nextech, and other unspecified investors.

 
Flare Therapeutics, Inc. deciphers the deoxyribonucleic acid (DNA) transcription factors to develop small molecule medicines in treating cancers and diseases. The firm provides drug discovery programs that address transcription factors focused on precision oncology.

The company will use the July 2026 funding to advance development of FX-111, prepare the candidate for clinical testing, and continue development of its prostate cancer pipeline.

## Funding rounds

- Series C, Jul 6, 2026, $85M — Third Rock Ventures, Nextech
- Series B, Mar 22, 2023, $123M — Novartis Venture Fund, Third Rock Ventures, Nextech, Pfizer Venture Investments, Casdin Capital, Invus Financial Advisors, Eli Lilly & Company, Memorial Sloan-Kettering Cancer Center Pension Plan, Eventide Asset Management, Boxer Capital, Agent Capital, Pavilion Capital Partners, GordonMD Global Investments
- Series A, May 13, 2021, $82M — Third Rock Ventures, Nextech, Casdin Capital, Invus Financial Advisors, Eventide Asset Management, Boxer Capital

## Investors

- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A, Series B, Series C
- Nextech (https://capitalatlas.ai/funds/nextech) — Series A, Series B, Series C
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A, Series B
- Invus Financial Advisors (https://capitalatlas.ai/funds/invus-financial-advisors) — Series A, Series B
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series A, Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series A, Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series B
- Eli Lilly & Company — Series B
- Memorial Sloan-Kettering Cancer Center Pension Plan — Series B
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series B
- Pavilion Capital Partners (https://capitalatlas.ai/funds/pavilion-capital-partners) — Series B
- GordonMD Global Investments (https://capitalatlas.ai/funds/gordonmd-global-investments) — Series B